Enzon Pharmaceuticals, Inc.
ENZN
$0.0998
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.46% | 56.00% | 10.38% | 14.39% | -8.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.46% | 56.00% | 10.38% | 14.39% | -8.86% |
| Operating Income | -50.46% | -56.00% | -2.20% | -14.39% | -2.37% |
| Income Before Tax | -47.75% | -23.68% | 19.15% | 98.15% | 213.33% |
| Income Tax Expenses | 217.67% | -35.53% | -92.31% | 102.86% | -25.76% |
| Earnings from Continuing Operations | -110.71% | -20.87% | 50.82% | 62.44% | 101.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.71% | -20.87% | 50.82% | 62.44% | 101.80% |
| EBIT | -50.46% | -56.00% | -2.20% | -14.39% | -2.37% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -75.19% | -32.14% | 27.66% | 37.78% | 51.14% |
| Normalized Basic EPS | -47.22% | -21.21% | 20.00% | 92.86% | 227.27% |
| EPS Diluted | -70.80% | -32.14% | 27.66% | 37.78% | 28.41% |
| Normalized Diluted EPS | -47.22% | -21.21% | 20.00% | 92.86% | 227.27% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -0.38% | -- |